Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FYN | P06241 | 2/20 | 0.47 |
| ▸ | TTK | P33981 | 2/20 | 0.47 |
| ▸ | MAPKAPK5 | Q8IW41 | 8/20 | 0.44 |
| ▸ | IDO1 | P14902 | 1/20 | 0.44 |
| ▸ | AURKA | O14965 | 3/20 | 0.43 |
| ▸ | BRAF | P15056 | 1/20 | 0.42 |
| ▸ | PTK6 | Q13882 | 1/20 | 0.41 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.41 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.40 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14767444 | 0.90 | TTK (0.54) | FYNTTKMAPKAPK5IDO1AURKA | |
| SCHEMBL12409302 | 0.81 | TTK (0.66) | FYNTTKMAPKAPK5AURKABRAF | |
| SCHEMBL3470478 | 0.81 | MAPKAPK5 (0.43) | FYNTTKMAPKAPK5IDO1AURKA | |
| SCHEMBL3471112 | 0.80 | FYN (0.47) | FYNTTKMAPKAPK5AURKABRAF | |
| SCHEMBL3467764 | 0.79 | DYRK3 (0.48) | FYNTTKIDO1BRAF | |
| SCHEMBL3466303 | 0.77 | GAA (0.53) | FYNTTKBRAF | |
| SCHEMBL3469696 | 0.76 | TTK (0.50) | TTKMAPKAPK5AURKAPTK6AURKB | |
| SCHEMBL8240292 | 0.76 | AURKA (0.70) | FYNTTKMAPKAPK5AURKAPTK6 | |
| SCHEMBL11939502 | 0.76 | BACE1 (0.44) | TTKMAPKAPK5AURKAAURKB | |
| SCHEMBL25447222 | 0.74 | TTK (0.57) | FYNTTKMAPKAPK5AURKAAURKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2567960-A2 | Imidazo[1,2-a]pyrazine compounds for treatment of viral infections such as hepatitis | Biofocus DPI Limited (GB) | 2013-03-13 | — | — | EP | disclosed |
| US-8362018-B2 | Substituted imidazo[1,2-a]pyrazine compounds useful for the treatment of viral infections | BIOFOCUS DPI, LTD. (GB) | 2013-01-29 | — | — | US | disclosed |
| US-8362018-B2 | Substituted imidazo[1,2-a]pyrazine compounds useful for the treatment of viral infections | BIOFOCUS DPI, LTD. (GB) | 2013-01-29 | — | — | US | disclosed |
| US-20110166147-A1 | IMIDAZOPYRAZINE COMPOUNDS | BIOFOCUS DPI, LTD. (GB) | 2011-07-07 | — | — | US | disclosed |
| US-20110166147-A1 | IMIDAZOPYRAZINE COMPOUNDS | BIOFOCUS DPI, LTD. (GB) | 2011-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166147-A1 | IMIDAZOPYRAZINE COMPOUNDS | CYP3A5, HAVCR2, CYP3A43 | FYN 3511/4885TTK 3239/4885MAPKAPK5 833/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.